Anteris Technologies Global Corp. is a structural heart company, which is engaged in providing cardiac care by science-driven and measurable advancements to restore heart valve patients to healthy function. Its lead asset, the DurAVR Transcatheter Heart Valve System (THV) consists of a single-piece, biomimetic valve made with its ADAPT tissue-enhancing technology and deployed with its ComASUR balloon-expandable delivery system. DurAVR THV is a novel transcatheter aortic valve for the treatment of aortic stenosis that is shaped to mimic the performance of a healthy human aortic valve. DurAVR THV’s single-piece design mimics the native anatomy of a human aortic valve, as compared to traditional three-piece aortic valves. The Company’s ADAPT is its proprietary anti-calcification tissue shaping technology that is designed to reengineer xenograft tissue into a pure, single-piece collagen bioscaffold. Its ComASUR delivery system is a physician-developed balloon expandable delivery system.
종목 코드 AVR
회사 이름Anteris Technologies Global Corp
상장일Dec 13, 2024
CEOPaterson (Wayne G)
직원 수136
유형Ordinary Share
회계 연도 종료Dec 13
주소860 Blue Gentian Road
도시EAGAN
증권 거래소NASDAQ OMX - NASDAQ BASIC
국가United States of America
우편 번호55121
전화16514930606
웹사이트https://anteristech.com/
종목 코드 AVR
상장일Dec 13, 2024
CEOPaterson (Wayne G)
지난 5년 동안 총
0.00
USD의 배당금이 분배되었습니다.

데이터 없음